

July 16, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: ir@ppmx.com

**Announcement of Presentation of PPMX-T003 Phase I
Interim Report at the 14th JSH International Symposium 2024**

Perseus Proteomics Inc. is pleased to announce that the interim report presentation of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera (PV) patients was made at the 14th JSH International Symposium 2024 in Hakodate held in Hakodate-shi, Hokkaido.

Date: July 13 – 14, 2024

Title: PHASE I STUDY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY (PPMX-T003) IN PATIENTS WITH POLYCYTHEMIA VERA (INTERIM REPORT)

Author: Tomoki Ito/First Department of Internal Medicine, Kansai Medical University

Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae/Department of Hematology, Osaka Metropolitan University

Kazunori Murai/Department of Hematology, Iwate Prefectural Central Hospital

Yoko Kubuki, Kazuya Shimoda/Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki

Tadashi Matsuura/Perseus Proteomics Inc.

Presenter: Tadashi Matsuura

This clinical trial has already finished as disclosed in “PPMX-T003: Announcement on the End of Phase I Clinical Trial for Polycythemia Vera (PV)” on June 28, 2024, however, the data lock and other procedures of the sixth patient are yet to be done. Dr. Matsuura, Executive Officer & CTO of the Company, presented that the primary evaluation item of safety and the secondary evaluation item of phlebotomy-free period (efficacy) have been confirmed based on the locked data of the five patients.

END